Literature DB >> 9892018

Functional analysis of a novel estrogen receptor-beta isoform.

B Hanstein1, H Liu, M C Yancisin, M Brown.   

Abstract

A new level of complexity has recently been added to estrogen signaling with the identification of a second estrogen receptor, ERbeta. By screening a rat prostate cDNA library, we detected ERbeta as well as a novel isoform that we termed ERbeta2. ERbeta2 contains an in-frame inserted exon of 54 nucleotides that results in the predicted insertion of 18 amino acids within the ERbeta hormone-binding domain. We also have evidence for the expression of both ERbeta1 and ERbeta2 in human cell lines. Competition ligand binding analysis of bacterially expressed fusion proteins revealed an 8-fold lower affinity of ERbeta2 for 17beta-estradiol (E2) [dissociation constant (Kd approximately 8 nM)] as compared with ERbeta1 (Kd approximately 1 nM). In vitro transcribed and translated ERbeta1 and ERbeta2 bind specifically to a consensus estrogen responsive element in a gel mobility shift assay. Furthermore, we show heterodimerization of ERbeta1 and ERbeta2 with each other as well as with ERalpha. In affinity interaction assays for proteins that associate specifically with the hormone-binding domain of these receptors, we demonstrate that the steroid receptor coactivator SRC-1 interacts in an estrogen-dependent manner with ERalpha and ERbeta1, but not with ERbeta2. In cotransfection experiments with expression plasmids for ERalpha, ERbeta1, and ERbeta2 and an estrogen-responsive element-containing luciferase reporter, the dose response of ERbeta1 to E2 was similar to that of ERalpha although the maximal stimulation was approximately 50%. In contrast, ERbeta2 required 100- to 1000-fold greater E2 concentrations for maximal activation. Thus, ERbeta2 adds yet another facet to the possible cellular responses to estrogen.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892018     DOI: 10.1210/mend.13.1.0234

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  26 in total

Review 1.  Estrogen receptor and the SERM concept.

Authors:  G G Kuiper; G J van den Bemd; J P van Leeuwen
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

Review 2.  A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition.

Authors:  Erin E Sundermann; Pauline M Maki; Jeffrey R Bishop
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

Review 3.  The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.

Authors:  D A Tonetti; V C Jordan
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 4.  The role of estrogens and estrogen receptors in normal prostate growth and disease.

Authors:  Gail S Prins; Kenneth S Korach
Journal:  Steroids       Date:  2007-11-12       Impact factor: 2.668

5.  Regulation of transcriptional activation function of rat estrogen receptor α (ERα) by novel C-terminal splice inserts.

Authors:  Pallob Kundu; Min Li; Rong Lu; Enrico Stefani; Ligia Toro
Journal:  Mol Cell Endocrinol       Date:  2014-11-07       Impact factor: 4.102

6.  Analysis of estrogen receptor isoforms and variants in breast cancer cell lines.

Authors:  Maie Al-Bader; Christopher Ford; Bushra Al-Ayadhy; Issam Francis
Journal:  Exp Ther Med       Date:  2011-03-10       Impact factor: 2.447

Review 7.  Structural and functional characteristics of oestrogen receptor β splice variants: Implications for the ageing brain.

Authors:  C K Kim; A Torcaso; A Asimes; W C J Chung; T R Pak
Journal:  J Neuroendocrinol       Date:  2018-02       Impact factor: 3.627

Review 8.  The normal and malignant mammary gland: a fresh look with ER beta onboard.

Authors:  M Warner; S Saji; J A Gustafsson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

9.  PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.

Authors:  Karine Belguise; Gail E Sonenshein
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 10.  Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk.

Authors:  Mitchell S Steiner; Sharan Raghow
Journal:  World J Urol       Date:  2003-02-14       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.